n a bit more deliberate than Jazz, but is coming along nicely. Antares started its royalty deals with a gel based platform, one being a royalty deal with Actavis, Inc. (NYSE: ACT) (formely Watson Pharma) for topical oxybutynin gel. Oxybutynin…
Tag: small cap pharma
Corrected Video: Market Commentary + Trade Watch Update 7/13/13
Some commentary from me on recent market action plus chart commentary on some of our recent picks. $GTXI $TSRX $SGMO $DRRX $SGMO $FB $BBY
Trius and General Market Commentary 6/5/13
Trius and General Market Commentary 6/5/13.. Answering critics and explaining market cap to price. Business basics as well.
Trius Therapeutics: The Next Big Small-Cap Biotech Mover?
Normally, I write about biotech companies with near-term catalysts I feel offer traders good long based trade opportunities heading into these catalysts. Every so often, I find a small cap biotech where I feel a speculation investment is truly warranted.…
Video Chart Analysis and Commentary on Trius Therapeutics ($TSRX)
Video Chart analysis and commentary on Trius Therapeutics (TSRX). From the Aegis analyst report, we read the following: In the wake of this data, we are raising our probability of success for tedizolid from 60% to 80%, which increases the…
BioDelivery Sciences Primed To Grab Its Share Of The $1.5 Billion Opioid Market
These days, prescription drugs have become a source for legal and illegal abuse. This abuse can lead to a medical diagnosis called opioid dependence, which is when a patient that is addicted to opioids such as morphine, hydrocodone, oxycodone, or…
Amarin Basic Company Thesis – Bearish 5/25/13 $AMRN
My basic opinion on Amarin. Like Vascepa, hate management and company structure. My opinion long term is bearish.
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Rally Insmed
The Orphan Drug Act was passed in January 1983 to encourage companies to develop drugs that treat rare medical conditions. Companies that receive Orphan Drug Status gain certain financial incentives such as a longer period of exclusivity, enhanced patent protection,…
Significant catalysts and an unfortunate PR mistake present an opportunity in AcelRx Pharmaceuticals.
With The positive result of the first phase III study, coupled with the positive responses of nurses and patients, AcelRx Pharmaceuticals (ACRX) saw a substantial increase in its share price, reaching a high of $5.19 in late November. As is often…
AcelRx Pharma Selloff Caused By Error In Recent Press Release
On March 12th, Acelrx (ACRX) released a pr covering its last quarter’s earnings. In the pr, the company stated that it had cash to last only to Q3 of this year. However, in the official conference call minutes, the company…
